Keywords: focus, exelon, alzheimer, disease, earlier, month, novartis

Focus On Exelon For Alzheimer's Disease

Article | 14 August 1997

• Print This

Earlier this month, Novartis' second-generation acetylcholinsteraseinhibitor was approved in its first market, Switzerland, for the treatment of mild-to-moderate Alzheimer's disease ( ...

Enjoying this article? To continue reading you need to login or subscribe.